AML BFM Study Group Department of Pediatric Oncology Hematology Medical High School Hannover Germany

CHU de Paris Hôpital Robert Debré France

Department of Pediatric Oncology Hematology Erasmus MC Sophia Children's Hospital Rotterdam The Netherlands

Dutch Childhood Oncology Group The Hague The Netherlands

Pediatric Hematology Oncology 2nd Medical School Charles University Prague Czech Republic

Princess Máxima Center for Pediatric Oncology Utrectht The Netherlands

Zobrazit více v PubMed

Balgobind BV, Hollink IH, Arentsen-Peters ST, et al. Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia. Haematologica. 2011;96(10):1478–1487. PubMed PMC

Kaspers GJ, Zwaan CM. Pediatric acute myeloid leukemia: towards high-quality cure of all patients. Haematologica. 2007;92(11):1519–1532. PubMed

Pui CH, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol. 2011;29(5):551–565. PubMed PMC

Creutzig UZM, Dworzak M, et al. Study AML-BFM 2004: improved survival in childhood acute myeloid leukemia without increased toxicity. Blood (ASH Annual Meeting Abstracts). 2010;116:Abstract #181.

Harrison CJ, Hills RK, Moorman AV, et al. Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. J Clin Oncol. 2010;28(16):2674–2681. PubMed

von Neuhoff C, Reinhardt D, Sander A, et al. Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. J Clin Oncol. 2010;28(16):2682–2689. PubMed

Hollink IH, van den Heuvel-Eibrink MM, Arentsen-Peters ST, et al. Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia. Haematologica. 2011;96(3):384–392. PubMed PMC

Hollink IH, Zwaan CM, Zimmermann M, et al. Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML. Leukemia. 2009;23(2):262–270. PubMed

Hollink IHIM, van den Heuvel-Eibrink MM, Arentsen-Peters STCJM, et al. NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. Blood. 2011;118(13):3645–3656. PubMed

de Rooij JD, Hollink IH, Arentsen-Peters ST, et al. NUP98/JARID1A is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia with a distinct HOX gene expression pattern. Leukemia. 2013;27(12):2280–2288. PubMed

Grossmann V, Tiacci E, Holmes AB, et al. Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. Blood. 2011;118(23):6153–6163. PubMed

Li M, Collins R, Jiao Y, et al. Somatic mutations in the transcriptional corepressor gene BCORL1 in adult acute myelogenous leukemia. Blood. 2011;118(22):5914–5917. PubMed PMC

Tiacci E, Grossmann V, Martelli MP, Kohlmann A, Haferlach T, Falini B. The corepressors BCOR and BCORL1: two novel players in acute myeloid leukemia. Haematologica. 2012;97(1):3–5. PubMed PMC

Flicek P, Amode MR, Barrell D, et al. Ensembl 2014. Nucleic Acids Res. 2014;42(Database issue):D749–755. PubMed PMC

Damm F, Chesnais V, Nagata Y, et al. BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders. Blood. 2013;122(18):3169–3177. PubMed

Loss-of-Function Mutations of BCOR Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia